Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027